No association between the functional cannabinoid receptor type 2 @entity71428 variants and XXXX in Turkish subjects.

@entity1 @entity71429 @entity31 @entity12332 @entity344 @entity29 @entity30 @entity71428
BACKGROUND/AIMS: The endocannabinoid system can exert beneficial effects on @entity344 , and @entity12332 ( @entity12332 ) agonists may represent a new therapeutic approach in @entity29 ( @entity29 ). A functional @entity12332 @entity71428 polymorphism ( @entity71429 ) in the @entity12332 gene has been shown to affect the immunomodulating properties of the @entity12332 receptor. We sought to investigate whether the functional @entity12332 @entity71428 polymorphism ( @entity71429 ) is associated with @entity29 susceptibility in a Turkish clinical sample. MATERIALS AND METHODS: A total of 202 @entity29 @entity1 , comprising 101 @entity30 ( @entity30 ) @entity1 and 101 @entity31 ( @entity31 ) @entity1 , and 101 healthy controls were included in the study. The @entity12332 @entity71428 polymorphism was genotyped using real-time PCR. RESULTS: There were no significant differences in the genotype frequencies of the three study groups. The odds ratio of the minor Q allele for @entity30 relative to the common R allele was not significant (OR =1.02, 95% CI =0.67-1.56, p=0.99). Similarly, the odds ratio of the minor Q allele for @entity31 relative to the common R allele did not reach statistical significance (OR =1.10, 95% CI =0.72-1.68, p=0.75). Moreover, the genotype frequencies did not show any significant association with the disease extent in either @entity30 (p= 0.71) or @entity31 @entity1 (p=0.59). CONCLUSION: These pilot findings suggest that @entity12332 @entity71428 polymorphism does not play a major role in genetic susceptibility to @entity29 or in its disease phenotypes among Turkish subjects.
